Janssen Therap Company Profile

What is the competitive landscape for JANSSEN THERAP

JANSSEN THERAP has one approved drug.

There are two US patents protecting JANSSEN THERAP drugs.

There are eighty-seven patent family members on JANSSEN THERAP drugs in thirty-nine countries and eighteen supplementary protection certificates in fifteen countries.

Summary for Janssen Therap

International Patents:	87
US Patents:	2
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Janssen Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-001	Dec 28, 2012		RX	Yes	Yes	8,546,428		Y	Y
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No	7,498,343		Y	Y
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-001	Dec 28, 2012		RX	Yes	Yes
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-001	Dec 28, 2012		RX	Yes	Yes

International Patents for Janssen Therap Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008068231
Montenegro	00131
Peru	20081350
South Korea	100733577
Austria	463482

Supplementary Protection Certificates for Janssen Therap Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1527050	CA 2014 00044	Denmark		PRODUCT NAME: BEDAKILIN ELLER ET FARMACEUTISK ACCEPTABELT SYRE-ELLER BASEADDITIONSSALT DERAF, HERUNDER BEDAKILINFUMARAT; REG. NO/DATE: EU/1/13/901 20140305
1527050	CR 2014 00044	Denmark		PRODUCT NAME: BEDAKILIN ELLER ET FARMACEUTISK ACCEPTABELT SYRE- ELLER BASEADDITIONSSALT DERAF, HERUNDER BEDAKILINFUMARAT; REG. NO/DATE: EU/1/13/901 20140305
1527050	PA2014032	Lithuania		PRODUCT NAME: BEDAQUILINUM; REGISTRATION NO/DATE: EU/1/13/901 20140305
1527050	92520	Luxembourg		PRODUCT NAME: BEDAQUILINE, OU SON SEL D ADDITION D ACIDE OU DE BASE PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE FUMARATE DE BEDAQUILINE. FIRST REGISTRATION: 20140307
1527050	PA2014032,C1527050	Lithuania		PRODUCT NAME: BEDAQUILINUM; REGISTRATION NO/DATE: EU/1/13/901 20140305

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Janssen Biotech
• Janssen Pharma
• Janssen Pharms
• Janssen Prods
• Janssen R And D

Pharmaceutical Competitive Landscape Analysis: Janssen Therap – Market Position, Strengths & Strategic Insights

Last updated: April 20, 2026

What is Janssen Therap's current market position?

Janssen Therap is a division of Johnson & Johnson focused on innovative therapies in various sectors, including oncology, immunology, infectious diseases, and neuroscience. The division has established a significant presence in global markets, with estimated revenue surpassing $20 billion in 2022, representing approximately 15% of Johnson & Johnson's total pharmaceutical sales.[1]

Its portfolio includes blockbuster drugs such as Stelara (ustekinumab), Darzalex (daratumumab), and Tremfya (guselkumab). The division's global footprint spans over 100 countries, with a strong emphasis on developed markets, notably the U.S., Europe, and Japan.

Janssen Therap's market positioning hinges on its diversified product portfolio, substantial R&D investments, and strategic acquisitions. The division maintains a competitive edge through continuous pipeline development and a focus on unmet medical needs in oncology and immunology.

How does Janssen Therap compare to key competitors?

Company	Estimated Revenue (2022)	Key Products	R&D Investment (2022)	Market Focus
Pfizer	$58.19 billion	Ibrance, Prevnar, Eliquis	$13.6 billion	Oncology, vaccines, cardiovascular
Roche	$58 billion	Herceptin, Avastin, Tecentriq	$10.7 billion	Oncology, diagnostics
Novartis	$51.6 billion	Cosentyx, Entresto, Kisqali	$9.0 billion	Oncology, ophthalmology, generics
Johnson & Johnson (Janssen)	$46 billion (pharma)	Stelara, Darzalex, Tremfya	~$11 billion (total)	Immunology, oncology, infectious diseases

Janssen Therap ranks among the top biopharma divisions globally but trails Pfizer and Roche in total revenue. Its strength lies in its earning consistency, especially in immunology and oncology segments, driven by established blockbusters and a pipeline focused on specialty medicines.

What are the core strengths of Janssen Therap?

Robust Product Portfolio

Janssen Therap has a series of high-performing drugs with worldwide approval. Stelara has achieved blockbuster status, generating over $8 billion annually. Darzalex and Tremfya further solidify Janssen's leadership in multiple myeloma and psoriasis, respectively.

Pipeline and Innovation

The division invests approximately 20% of its revenue into R&D, with over 100 clinical trials ongoing.[2] Its pipeline focuses on immune-oncology, auto-inflammatory diseases, and infectious diseases, with several Phase III assets expected to launch over the next three years.

Strategic Collaborations and Acquisitions

Janssen enhances its pipeline through acquisitions such as the 2017 purchase of Actelion, expanding its pulmonary hypertension and rare diseases portfolio. Collaborations with biotech firms accelerate access to emerging technologies like mRNA platforms and gene therapies.

Regulatory and Market Access

Janssen has a track record for successful regulatory submissions globally. It has tailored its commercialization strategies to optimize market access and reimbursement negotiation, especially in high-growth regions.

Where are strategic opportunities and challenges?

Opportunities

• Expansion into emerging markets through local partnerships.
• Development of biosimilars to maintain competitive pricing and market share.
• Advancement of personalized medicine approaches leveraging biomarkers and genomic data.

Challenges

• Patent expirations threaten revenue stability; Stelara's patent loss is projected for 2023.
• Intense competition from biotech firms employing novel modalities like cell therapy.
• Pricing pressure resulting from regulatory reforms and payer negotiations.

How is Janssen Therap planning to sustain growth?

The division prioritizes pipeline diversification, aiming at first-in-class therapies. It fosters innovation by investing in gene editing, cellular therapies, and digital health integrations. The company also emphasizes lifecycle management, extending patent protections via new indications.

Conclusion

Janssen Therap maintains a competitive footing through diversified pipeline development, strong market presence, and strategic acquisitions. Its core strengths reside in high-value specialty medicines, especially in immunology and oncology. However, impending patent expirations and increasing competition necessitate continual innovation and strategic agility.

---

Key Takeaways

• Janssen Therap had over $20 billion in revenue in 2022, primarily from immunology and oncology.
• Its product portfolio includes high-revenue drugs like Stelara, Darzalex, and Tremfya.
• The division invests heavily in R&D, focusing on emerging technologies and personalized medicine.
• Its competitive position benefits from strategic collaborations and lifecycle management.
• Future growth hinges on pipeline success, market expansion, and navigating patent cliffs.

FAQs

1. What are Janssen Therap's most profitable drugs?
   Stelara, Darzalex, and Tremfya generate significant revenue, with Stelara alone exceeding $8 billion annually.

2. How does Janssen plan to offset patent expirations?
   It focuses on pipeline diversification, early-stage innovation, and extending drug indications.

3. Which regions are critical for Janssen's growth?
   The U.S., Europe, Japan, and emerging markets like China and India.

4. What innovative therapies is Janssen exploring?
   Gene therapies, CAR-T cell therapies, and digital health integrations.

5. How does Janssen's R&D investment compare to competitors?
   It allocates approximately 20% of revenue to R&D, similar to Pfizer and Roche, emphasizing innovation.

---

References

[1] Johnson & Johnson Annual Report (2022).
[2] Janssen Global Pipeline Overview (2023).